Stem Cell Therapy for Crohn's disease in Turkey – Istanbul
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Clinical guide to MSC therapy for Crohn's disease in Turkey: luminal vs fistulising disease, evidence limits, candidacy, exclusions and Istanbul planning.
Can stem cell therapy help Crohn's disease?
Local mesenchymal stem cell therapy has approved use in one specific indication — complex perianal fistulas in Crohn's disease (darvadstrocel, EU approval). Systemic MSC administration for luminal Crohn's disease is not approved and has inconsistent trial evidence. Established therapies — biologics such as anti-TNF, anti-integrin, IL-23 inhibitors, and JAK inhibitors — remain the evidence-based mainstay for luminal disease.
Key facts
- Approved use
- Complex perianal fistulas (darvadstrocel, EU)
- Luminal disease evidence
- Not approved; inconsistent trial data
- Standard care
- Biologics (anti-TNF, anti-integrin, IL-23) and small molecules
What we know
- Darvadstrocel demonstrated healing of complex perianal fistulas in randomised trials and received EU marketing authorisation.
What remains uncertain
- Whether systemic MSC administration adds anything beyond current biologics for luminal Crohn's disease.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Evidence at a glance — Crohn's disease (including perianal fistulas)
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — including controlled studies
- Randomised trials?
- Randomised trials of local MSC therapy for perianal fistulas; the confirmatory ADMIRE-CD II trial did not meet its endpoint
- Main outcomes studied
- Fistula closure on MRI and examination
- Remission rates
- CDAI
- Safety
- Long-term evidence
- Limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved MSC product for Crohn's disease. Darvadstrocel is not FDA approved.
- European Union (EMA): Darvadstrocel (Alofisel) held an EU authorisation for complex perianal fistulas in Crohn's disease from 2018; the marketing authorisation was withdrawn in 2024 after a confirmatory trial did not meet its endpoint. There is no EMA-authorised MSC medicine for luminal Crohn's disease.
- United Kingdom (MHRA): No MHRA-authorised MSC medicine for Crohn's disease.
- Türkiye (Ministry of Health): Ministry of Health–licensed centres only, as clinical research or individual (exceptional) use.
- Role at our centre
- Supportive consideration alongside standard care
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Documented
Sources
- Systematic reviews and meta-analyses — Crohn's disease (including perianal fistulas) — PubMed
- Randomised controlled trials — Crohn's disease (including perianal fistulas) — PubMed
- Registered MSC trials — Crohn's disease (including perianal fistulas) — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
Records before recommendations
A proposed route is discussed only after diagnosis, investigations, current care and travel fitness have been reviewed.
No outcome guarantee
The evidence, uncertainty and reasons not to proceed are explained. Established care remains part of the decision.
Plan for continuity
Istanbul logistics, discharge documents and follow-up should connect with the clinician managing care at home.
A decision guide for patients comparing care
This page is for patients and families researching regenerative options for Crohn's disease and comparing an Istanbul medical review with care available at home. It explains the evidence limits, questions that determine candidacy, reasons not to travel, protocol decisions, realistic expectations, costs and return-home follow-up.
Before considering stem cell therapy for Crohn's disease
The key question: Is the clinical problem active luminal disease, a complex perianal fistula or another complication—and what established options have been reviewed?
Evidence status
Evidence differs between local cell therapy for complex perianal fistulas and systemic treatment for luminal Crohn's disease. These uses must not be conflated.
Standard care first
Gastroenterology management, nutrition, biologic or small-molecule therapy, imaging, endoscopy and colorectal surgery remain central.
What the review checks
Disease location and activity, fistulas or abscesses, imaging, endoscopy, biologics, steroid exposure, nutrition, infection and previous surgery.
When we redirect
Abscess, obstruction, perforation, sepsis, severe malnutrition or uncontrolled flare requires urgent gastroenterology or surgical care.
Planning treatment in Istanbul
Coordinate medication timing, nutrition, toilet access, thrombosis risk, companion needs and records for the home IBD team.
How are stem cell and exosome approaches discussed for Crohn's disease?
The evidence for local cell therapy in selected complex perianal fistulas is not the same as evidence for systemic MSC treatment of luminal Crohn's disease. The location, product, delivery route and clinical question must be stated clearly.
Before any regenerative discussion, abscess, obstruction, infection, nutrition and current IBD therapy must be reviewed. Exosome or broad intestinal-healing claims should not be inferred from fistula-specific evidence.
Who may be considered?
Candidacy is never decided from age or diagnosis alone. A medical review looks for a clear clinical question, stable health, appropriate prior care and goals that can be followed after return home.
- A clearly defined luminal, fistulising or postoperative clinical problem
- Recent endoscopy or imaging and a review of current advanced therapy
- No untreated abscess, obstruction, sepsis or severe malnutrition
Who may not be suitable?
Abscess, obstruction, perforation, sepsis, severe malnutrition or uncontrolled flare requires urgent gastroenterology or surgical care.
Active infection, unstable medical disease, pregnancy, active cancer treatment or inability to complete safe follow-up also require postponement, redirection or further specialist review.
How is a protocol for Crohn's disease planned?
Route, dose, session count and stay length cannot be responsibly prescribed from a webpage. The written plan follows record review and should explain why each element is being proposed.
- 1
Records and diagnosis review
Recent specialist reports, investigations, medication and previous treatment are reviewed to confirm the clinical question and whether Crohn's disease is stable enough for elective travel.
- 2
Product and route discussion
If an investigational option is discussed, the team should identify the cell or exosome product, source, testing, proposed route and why that route is being considered. No fixed dose or route is appropriate for every patient.
- 3
Individual written plan
Session count, timing, monitoring and supportive care are documented only after medical review. The plan should explain uncertainty, alternatives and what would cause treatment to be postponed or declined.
- 4
Discharge and follow-up handover
Patients receive product and procedure documentation, medication instructions, warning signs and a follow-up plan that can be shared with their clinician at home.
What results can realistically be expected?
The purpose of follow-up is to measure safety and agreed clinical goals—not to retrofit ordinary variation into a success claim.
- There is no guaranteed response and no promise of cure, reversal, remission, tissue regrowth or stopping established medication.
- Any goals should be condition-specific and measurable—for example function, symptoms, participation or rehabilitation tolerance—rather than a broad claim of regeneration.
- The timing of any change is uncertain. Immediate post-procedure observations, later clinical review and longer-term follow-up serve different purposes; published research cannot predict an individual outcome.
- No change, temporary symptoms or the need for further local assessment are possible outcomes and should be discussed before travel.
Why patients consider StemCell Longevita for Crohn's disease
Patients may choose StemCell Longevita when they want an Istanbul review pathway built around records, written decisions and return-home coordination rather than a promise of results. These are the service standards to confirm during consultation:
Records are reviewed before a treatment recommendation or travel booking is requested
The medical team can explain why an enquiry may be declined or redirected
The proposed product, source, testing, route and traceability documents are identified in writing
Investigational options are distinguished from established treatment and medication is not stopped without the home clinician
The quotation separates clinical services, travel support, exclusions and potential extra costs
Discharge documents and a follow-up pathway are prepared for continuity with the home specialist
International patient journey for Crohn's disease
Coordinate medication timing, nutrition, toilet access, thrombosis risk, companion needs and records for the home IBD team.
- 1
Private record review
Send recent reports, imaging or test results and a current medication list. The team may request more information or advise against travel.
- 2
Written planning before booking
Confirm the proposed intervention, evidence status, exclusions, estimated stay, companion or accessibility needs, package inclusions and total quoted cost.
- 3
Assessment in Istanbul
Clinical review on arrival confirms that health status and records still support the plan. Treatment should be paused if new risks are identified.
- 4
Discharge and return home
Travel timing and support are adapted to Crohn's disease. Warning signs, medication continuity and relevant documents are reviewed before departure.
- 5
Remote follow-up
Scheduled check-ins document safety and agreed outcomes, while the home specialist remains responsible for established disease management and urgent care.
How much does treatment for Crohn's disease cost in Turkey?
A responsible quotation follows medical review. It should show the proposed clinical service and travel support separately enough for you to compare it with options in the UK, US, Germany or another home country.
- Condition-page prices are not quoted before records are reviewed because product, route, session structure, monitoring and travel support can differ.
- Ask for one written total showing the clinical service, laboratory or product documentation, hospital fees, tests, medication, transfers, accommodation and follow-up—and what is not included.
- Comparisons with the UK, US, Germany or another home country should compare like-for-like private services, not imply that an investigational intervention is equivalent to licensed standard care.
Frequently asked questions about Crohn's disease
Related clinical questions
Where this page sits in the wider picture.